IDH1 and glioblastoma: The more common and severe IDH-wild type displays a greater proportion of CD11b+, CD45+ expressing macrophages whose activation initiates anti-inflammatory responses and contributes to poorer patient outcomes, compared to IDH-mutant GBM with a greater microglial concentration, promoting a pro-inflammatory TME [46].